MO Altria
Still a melting ice cube, and the market now prices an even slower melt than before.
The story
Altria is the dominant US cigarette maker. Marlboro's pricing power more than offsets volume declines of about 8-10% a year, which keeps revenue roughly flat and operating margins near 57%. It is a mature, slowly declining cash machine. Its smoke-free efforts (NJOY, on!) have not yet replaced the cigarette economics, so the business is still a melting ice cube that returns nearly all of its cash to shareholders.
No facts changed, so I kept every driver. TTM revenue of $20.63B and a 57.1% margin fit the story of price increases offsetting volume loss, and the reported margin swings reflect one-off items, not a change in the core business. The price rose from 71.42 to 78.9 while the fundamentals stayed the same. The market is capitalizing a 5%+ dividend yield, and the core DCF leaves out the ABI stake and other non-operating assets, which explains part of the gap.
Value drivers
| Revenue growth (Y1) | -1.0% |
| Terminal growth | -1.0% |
| Forecast horizon | 5y |
| Target operating margin | 58.0% |
| Years to target margin | 3 |
| Sales-to-capital | 2.00 |
| Beta | 0.60 |
| Failure probability | 5.0% |
| Cost of capital (WACC) | 7.3% |
| Terminal WACC | 8.8% |
Valuation bridge
| PV of explicit FCFF | 34.83B |
| PV of terminal value | 59.40B |
| Equity value | 69.31B |
| ÷ shares → per share | $41.66 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 20.43B | -1.0% | 57.4% | 8.67B | 0 | 8.67B | 8.08B |
| 2 | 20.22B | -1.0% | 57.7% | 8.63B | 0 | 8.63B | 7.49B |
| 3 | 20.02B | -1.0% | 58.0% | 8.59B | 0 | 8.59B | 6.95B |
| 4 | 19.82B | -1.0% | 58.0% | 8.51B | 0 | 8.51B | 6.41B |
| 5 | 19.62B | -1.0% | 58.0% | 8.42B | 0 | 8.42B | 5.91B |
Key risks
- Cigarette volume declines speed up beyond 10% a year and pricing power erodes
- FDA menthol or nicotine-cap rules, or rising excise taxes
- Illicit disposable vapes take share and NJOY litigation or import bans stall the smoke-free transition
Catalysts
- Enforcement against illicit vapes shifts share to authorized products such as NJOY and on!
- Buybacks funded by ABI stake monetization, plus steady dividend growth